Clinical significance of RET mutation screening in a pedigree of multiple endocrine neoplasia type 2A

Ying,Rongbiao; Feng,Jun

doi:10.3892/mmr.2016.5371

Clinical significance of RET mutation screening in a pedigree of multiple endocrine neoplasia type 2A

Authors:
- Rongbiao Ying
- Jun Feng
View Affiliations

Affiliations: Department of Surgical Oncology, Taizhou Cancer Hospital, Taizhou Branch of Fudan University, Taizhou, Zhejiang 317502, P.R. China
Published online on: June 6, 2016 https://doi.org/10.3892/mmr.2016.5371
Pages: 1413-1417

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The clinical characteristics and RET proto-oncogene (RET‑PO) mutation status of a patient with multiple endocrine neoplasia type 2A pedigree (MEN2A) was analyzed with the aim of preliminarily exploring the molecular mechanisms and clinical significance of the disease. Clinical characteristics of a single MEN2A patient were analyzed. Genomic DNA was extracted from the peripheral blood of the proband and 10 family members. The 21 exons of RET‑PO were PCR amplified and the amplified products were sequenced. Of the family members, 5 exhibited a C634Y (TGC→TAC) missense mutation in exon 11 of RET‑PO, among which 2 family members were screened as mutation carriers, while the others did not exhibit clinical symptoms of the mutation. The screening and analysis of RET‑PO mutations for the MEN2A proband and the family members suggests potential clinical phenotypes and enables assessment of the risk of disease development, thus providing useful information for determining the surgical timing of preventive thyroid gland removal.

View Figures

View References

1	Raue F and Frank-Raue K: Update multiple endocrine neoplasia type 2. Fam Cancer. 9:449–557. 2010. View Article : Google Scholar : PubMed/NCBI
2	Wagner SM, Zhu S, Nicolescu AC and Mulligan LM: Molecular mechanisms of RET receptor-mediated oncogenesis in multiple endocrine neoplasia 2. Clinics (Sao Paulo). 67(Suppl 1): S77–S84. 2012. View Article : Google Scholar
3	American Thyroid Association Guidelines Task Force; Kloos RT, Eng C, Evans DB, Francis GL, Gagel RF, Gharib H, Moley JF, Pacini F, Ringel MD, et al: Medullary thyroid cancer: Management guidelines of the American thyroid association. Thyroid. 19:565–612. 2009. View Article : Google Scholar : PubMed/NCBI
4	Qi XP, Ying RB, Ma JM, Liu WT, Du ZF, Fei J, Yang CP, Song QZ, Jin HY, Chen ZG, et al: Case report: A p.C618S RET proto-oncogene germline mutation in a large Chinese pedigree with familial medullary thyroid carcinoma. Fam Cancer. 11:131–136. 2012. View Article : Google Scholar
5	Hibi Y, Ohye T, Ogawa K, Shimizu Y, Shibata M, Kagawa C, Mizuno Y, Kurahashi H and Iwase K: A MEN2A family with two asymptomatic carriers affected by unilateral renal agenesis. Endocr J. 61:19–23. 2014. View Article : Google Scholar
6	Sakorafas GH, Friess H and Peros G: The genetic basis of hereditary medullary thyroid cancer: Clinical implications for the surgeon, with a particular emphasis on the role of prophylactic thyroidectomy. Endocr Relat Cancer. 15:871–884. 2008. View Article : Google Scholar : PubMed/NCBI
7	Roy M, Chen H and Sippel RS: Current understanding and management of medullary thyroid cancer. Oncologist. 18:1093–1100. 2013. View Article : Google Scholar : PubMed/NCBI
8	Ferguson JW, Richard JJ, O'Laughlin JW and Banks CV: Simultaneous spectrophotometric determination of calcium and magnesium with chlorophosphonazo III. Anal Chem. 36:796–799. 1964. View Article : Google Scholar
9	Mulligan LM, Kwok JB, Healey CS, Elsdon MJ, Eng C, Gardner E, Love DR, Mole SE, Moore JK, Papi L, et al: Germ-line mutations of the RET proto-oncogene in multiple endocrine neoplasia type 2A. Nature. 363:458–460. 1993. View Article : Google Scholar : PubMed/NCBI
10	Donis-Keller H, Dou S, Chi D, Toshima K, Lairmore TC, Howe JR, Moley JF, Goodfellow P and Wells SA Jr: Mutations in the RET proto-oncogene are associated with MEN 2A and FMTC. Hum Mol Genet. 2:851–856. 1993. View Article : Google Scholar : PubMed/NCBI
11	Gschwind A, Fischer OM and Ullrich A: The discovery of receptor tyrosine kinases: Targets for cancer therapy. Nat Rev Cancer. 4:361–370. 2004. View Article : Google Scholar : PubMed/NCBI
12	Machens A, Niccoli-Sire P, Hoegel J, Frank-Raue K, van Vroonhoven TJ, Roeher HD, Wahl RA, Lamesch P, Raue F, Conte-Devolx B, et al: Early malignant progression of hereditary medullary thyroid cancer. N Engl J Med. 349:1517–1525. 2003. View Article : Google Scholar : PubMed/NCBI
13	Pasini B, Ceccherini I and Romeo G: RET mutations in human disease. Trends Genet. 12:138–144. 1996. View Article : Google Scholar : PubMed/NCBI
14	Qi XP, Chen XL, Ma JM, Du ZF, Fei J, Yang CP, Cheng J, Song QZ, Han JS, Jin HY, et al: RET proto-oncogene genetic screening of families with multiple endocrine neoplasia type 2 optimizes diagnostic and clinical management in China. Thyroid. 22:1257–1265. 2012. View Article : Google Scholar : PubMed/NCBI
15	Mulligan LM, Eng C, Healey CS, Clayton D, Kwok JB, Gardner E, Ponder MA, Frilling A, Jackson CE, Lehnert H, et al: Specific mutations of the RET proto-oncogene are related to disease phenotype in MEN 2A and FMTC. Nat Genet. 6:70–74. 1994. View Article : Google Scholar : PubMed/NCBI
16	Santoro M, Carlomagno F, Romano A, Bottaro DP, Dathan NA, Grieco M, Fusco A, Vecchio G, Matoskova B, Kraus MH, et al: Activation of RET as a dominant transforming gene by germline mutations of MEN2A and MEN2B. Science. 267:381–383. 1995. View Article : Google Scholar : PubMed/NCBI
17	Sippel RS, Kunnimalaiyaan M and Chen H: Current management of medullary thyroid cancer. Oncologist. 13:539–547. 2008. View Article : Google Scholar : PubMed/NCBI
18	Sawka AM, Jaeschke R, Singh RJ and Young WF Jr: A comparison of biochemical tests for pheochromocytoma: Measurement of fractionated plasma metanephrines compared with the combination of 24-hour urinary metanephrines and catecholamines. J Clin Endocrinol Metab. 88:553–558. 2003. View Article : Google Scholar : PubMed/NCBI
19	Milan SA, Sosa JA and Roman SA: Current management of medullary thyroid cancer. Minerva Chir. 65:27–37. 2010.PubMed/NCBI
20	Roman S, Lin R and Sosa JA: Prognosis of medullary thyroid carcinoma: Demographic, clinical and pathologic predictors of survival in 1252 cases. Cancer. 107:2134–2142. 2006. View Article : Google Scholar : PubMed/NCBI
21	Scollo C, Baudin E, Travagli JP, Caillou B, Bellon N, Leboulleux S and Schlumberger M: Rationale for central and bilateral lymph node dissection in sporadic and hereditary medullary thyroid cancer. J Clin Endocrinol Metab. 88:2070–2075. 2003. View Article : Google Scholar : PubMed/NCBI
22	Fleming JB, Lee JE, Bouvet M, Schultz PN, Sherman SI, Sellin RV, Friend KE, Burgess MA, Cote GJ, Gagel RF and Evans DB: Surgical strategy for the treatment of medullary thyroid carcinoma. Ann Surg. 230:697–707. 1999. View Article : Google Scholar : PubMed/NCBI
23	White ML, Gauger PG and Doherty GM: Central lymph node dissection in differentiated thyroid cancer. World J Surg. 31:895–904. 2007. View Article : Google Scholar : PubMed/NCBI
24	Chen H, Sippel RS, O'Dorisio MS, Vinik AI, Lloyd RV and Pacak K; North American Neuroendocrine Tumor Society (NANETS): The North American Neuroendocrine Tumor Society consensus guideline for the diagnosis and management of neuroendocrine tumors: Pheochromocytoma, paraganglioma, and medullary thyroid cancer. Pancreas. 39:775–783. 2010. View Article : Google Scholar : PubMed/NCBI
25	Krampitz GW and Norton JA: RET gene mutations (genotype and phenotype) of multiple endocrine neoplasia type 2 and familial medullary thyroid carcinoma. Cancer. 120:1920–1931. 2014. View Article : Google Scholar : PubMed/NCBI
26	Rodriguez JM, Balsalobre M, Ponce JL, Ríos A, Torregrosa NM, Tebar J and Parrilla P: Pheochromocytoma in MEN 2A syndrome. Study of 54 patients. World J Surg. 32:2520–2526. 2008. View Article : Google Scholar : PubMed/NCBI
27	Inabnet WB, Caragliano P and Pertsemlidis D: Pheochromocytoma: Inherited association, bilaterality and cortex preservation. Surgery. 128:1007–1011. 2000. View Article : Google Scholar